The XL TP53/NF1 probe is a qualitative, non-automated test for the detection of isochromosomes 17q, deletions of the TP53 gene region at 17p13 and deletions of the NF1 gene region at 17q11.2 by fluorescence in situ hybridization (FISH). The product is intended as a diagnostic aid and assists in disease monitoring. The test population for the detection of isochromosome 17q consists of patients with confirmed or suspected acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myelodysplastic neoplasms (MDS) and non-Hodgkin-lymphomas (NHL). The test population for the detection of deletions of the TP53 gene region consists of patients with confirmed or suspected acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), myelodysplastic neoplasms (MDS), multiple myeloma (MM) and non-Hodgkin-lymphomas (NHL).The test population for the detection of deletions of the NF1 gene region at 17q11.2 consists of patients with confirmed or suspected acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), myelodysplastic neoplasms (MDS) and myeloproliferative neoplasms (MPN). Hybridization is to be performed on methanol/acetic-acid fixed cells derived from bone marrow or peripheral blood for ALL, AML, CLL, CML, CMML, MDS and MPN, on methanol/acetic-acid fixed plasma cells for MM and on methanol/acetic-acid fixed cells derived from involved lymph node, involved bone marrow or other involved tissue for NHL.